Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...

Is your company bracing for Milton or working to provide aid in anticipation of the storm? | Pfizer—which opened a global hub ...

Pfizer CEO Albert Bourla plans to meet activist investor Starboard Value, the Financial Times reported on Tuesday, citing ...

Shares of Pfizer (NYSE: PFE) have been stuck in the mud since December 2022, with its shares down more than 45% over that ...

Boehringer Ingelheim has rolled into an alliance with undruggable target specialist Circle Pharma, putting together a package ...

Pfizer in recent months has implemented aggressive cost-cutting measures to help it weather the steep decline in sales of its ...

As activist Starboard teams up with former Pfizer executives, the pharma giant’s lack of focus is in the spotlight.

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

Here's what investors need to know today. The Department of Justice (DOJ) has submitted a filing giving a federal court a ...

Pfizer (PFE) discontinues development of experimental RSV therapy sisunatovir from pipeline in a blow for its $525M ...

Starboard has a roughly $1 billion stake in the drugmaker and approached former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio, both of whom expressed interest in supporting the activist investor's ...